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Introduction 
 
PhIP is a Dietary Carcinogen that May Pose Heightened Risk to African-American Men 
African American (AA) men, who compared to Caucasians die nearly twice as 
much from prostate cancer (PC), also take in about twice as much of the predominant 
U.S. dietary heterocyclic amine, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine 
(PhIP) (Bogen and Keating, 2001), which occurs primarily in well-cooked chicken and 
beef.  Heterocyclic amines (HAs) are potent mutagens formed in meats, chicken and 
fish as it is cooked to higher-doneness levels by heat-intensive cooking methods 
(Thompson et al., 1987; Keating et al., 1999, 2000). HAs also cause cancer at a variety 
of sites in multiple bioassay animal species/strains/sexes, as well as at multiple sites 
within many of species/strains/sexes tested (Bogen, 1994). A predominant HA found in 
cooked and particularly in well-done chicken and beef is 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP) (Felton et al., 1984, 1986; Felton and Knize, 1990a-
b; Sinha et al., 1995). Dietary exposure to PhIP has been shown to induce colon, 
intestinal and mammary adenocarcinomas in rats (Ohgaki et al., 1986; Ochiai et al., 
1991; Ito et al., 1991; Ito et al., 1997; Ghoshal et al., 1994), as well as prostate cancer 
in rats (Shirai et al., 1997,1999). HAs are metabolically activated by P450 and N-
acetyltransferase enzymes to activated forms that bind covalently to (among other 
targets) DNA in tissues (including in prostate) where HAs induce cancer in rats 
(Thorgeirsson et al., 1983; Thorgeirsson, 1984; Rosenkranz and Mermeistein, 1985; 
Sato et al., 1986; Kato and Yamazoe, 1987; Snyderwine and Battula, 1989; McManus 
et al., 1990; Turesky et al., 1991; Davis et al., 1993; Kaderlik et al., 1994a-b; Takahashi 
et al., 1998; Schut and Snyderwine, 1999; Gooderham et al., 2002). In male lacI 
trangenic rats, a diet containing 200 ppm PhIP was shown to be highly mutagenic in 
prostate tissue (Stuart et al., 2000). In cultured human prostate tissue and primary 
prostate cells, PhIP is metabolically activated to mutagenic forms that covalently bind to 
and damage DNA (Williams et al., 2000; Lawson and Kolar, 2002; Martin et al., 2002; Di 
Paolo et al., 2005). 
 
PC and African-American men 
 In the U.S., prostate cancer (PC) is a leading cause of cancer death among men, 
with African Americans having the highest age-specific prostate cancer rate in the 
world, and a >2-fold higher rate of mortality for PC than white men in the U.S.(Miller et 
al., 1996; Robbins et al., 1998; Hsing et al., 2000). Although family (particularly 
father/brother) history of PC is clearly linked to substantially elevated PC risk 
(Schuurman et al., 1999; Hemminki and Czene, 2002; Zeegers et al., 2003; Hemminki 
and Chen, 2005) and a human-PC-specific chromosome translocation has been 
identified (Tomlins et al., 2005), there is (as for most other cancers) no evidence for a 
predominant heritable factor for PC. Racial-ethnic differences in levels of testosterone-
related hormones and related genetic controls on hormone-induced prostate growth 
have been hypothesized to explain or contribute to corresponding racial-ethnic 
differences in PC risk, but their role remains unclear (Ross et al., 1998; Pettaway, 1999; 
Hsing, 2001). Even if hormonally mediated background processes do affect PC risk, 
dietary exposures to genotoxic HA carcinogens may act independently or interact 
synergistically with such hormonal processes to further modify PC risk. 
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HA, Meat, Other Dietary Factors, and PC Risk 
 Substantial geographical variations in PC incidence indicate the importance of 
one or more dietary or other environmental factors (Minami et al., 1993; Mettlin, 1997; 
Angwafo, 1999). Dietary intake of animal or saturated fat is the environmental factor 
most consistently linked to significantly increased PC risk in previous studies, 
particularly among African-American men, though these associations appear too weak 
to explain more than a small fraction of observed racial-ethnic differences in PC risk 
(Whittemore et al., 1995; Hayes et al., 1999; Kolonel et al., 1999; Daniels et al., 2004), 
as also appears to be the case for other environmental/dietary factors examined such 
calcium, cruciferous vegetables, vitamin D, UV from sunlight, lycopene, and body size 
(Giovannucci et al., 1997, 1998; Cohen et al., 2000; Chan and Giovannucci, 2001a-b; 
Kristal and Lampe, 2002; Bodiwala et al., 2003). Because cooked-meat intake is 
positively associated with total saturated-fat intake (USDA, 1998), previous studies that 
focused on animal or saturated fat per se could have estimated effects due largely or 
entirely to meat-related HA intakes. 
 
 Consumption of cooked meats and associated HAs have been linked to 
increased risks of colorectal adenoma/adenocarcinoma and of cancer of the stomach, 
breast, lung and prostate (Mills et al., 1989; Shiffman and Felton, 1990; Gerhardsson de 
Verdier et al., 1991; Talamini et al., 1992; Lang et al., 1994; De Stefani et al., 1995; 
Ewings and Bowie, 1996; Probst-Hensch et al., 1997; Ward et al., 1997; Kampman et 
al., 1999; Norrish et al., 1999; Sinha et al., 1998a, 1999a-b; Zheng et al., 1998, 1999; 
Murtaugh et al., 2004), while fewer studies found no such associations (Lyon and 
Mahoney, 1988; Muscat and Wynder, 1994; Augustsson et al., 1999). Positive studies 
include those in which HA exposure was quantified adjusting for factors expected to 
determine HA intake—namely, meat type, consumption frequency, cooking method, and 
cooking doneness. A potential link between PhIP intake, in particular, and the elevated 
risk of PC experienced by African-American compared to Caucasian men is suggested 
by relatively greater levels of PhIP and its metabolites detected in urine sampled from 
the latter vs. the former group (Kidd et al., 1999), although urine analysis only provides 
a measure of PhIP exposure within 12-24 hours prior to sampling (Malfatti et al., 1999). 
Such a link is also supported by studies using meat- and cooking-method-specific HA-
concentration estimates from multi-laboratory sets of experimental cooking data 
(Keating and Bogen, 2001) to assess intakes of PhIP and other HAs by >20,000 U.S. 
(including >3,000 African-American) participants in the nationwide, stratified, random-
sample U.S. Continuing Survey of Food Intakes by Individuals (CSFII) (USDA, 1993, 
1998). Analyzed by age-, sex, and race/ethnicity, these HA-exposure assessments 
found at all ages that African-American males consume on average at least twice as 
much PhIP (and total HA) per kg body weight per day as do U.S. Caucasian males, and 
that for both groups there is a significant positive (albeit small) correlation between 
estimated mean intakes of PhIP and those of saturated or total fat (Keating and Bogen, 
2001; Bogen and Keating, 2001). 
 
Although the study comparing HA intake (primarily from cooked lamb) and PC 
risk in New Zeeland men by Norrish et al. (1999) found no significant PhIP-related 
6 
 
associations involving PC, that study did report a significant association between PC 
risk and consumption of beefsteak by higher cooking-doneness category (2-sided ptrend 
= 0.008). Several aspects of that study suggest it may have had limited power to assess 
potential associations between PC and HA or PhIP intake in the U.S. The incidence of 
PC in New Zeeland is only half that of Caucasian men in the U.S. (Hsing et al. 2000). 
Average meat (primarily lamb) consumption by subjects in the Norrish et al. study (~150 
g/d) was well below that of U.S. Caucasian men (260 g/d) and very well below that of 
African-American men (304 g/d) (USDA, 1998; Table 10A). Moreover, the minimum 
PhIP intake (224 ng/d) in the top exposure quartile of Norrish et al. study subjects was 
well below the estimated average PhIP intakes by U.S. Caucasian (390 ng/d) and by 
African-American (600 ng/d) men (Bogen and Keating 2001). 
 
PC Screening and PC 
 Periodic screening for plasma levels of Prostate-Specific Antigen (PSA) is useful 
for early detection of PC as well as benign prostatic hyperplasia (BPH) because PSA 
levels in serum are positively associated with age, prostate volume, and prostatic 
neoplastic disease (Carter et al., 1992; Oesterling et al., 1993; Etzioni et al., 1999). 
Significantly higher PSA levels are found in African-Americans than in whites, even after 
adjustment for age and prostate volume (in men without PC) and for PC grade and 
stage (in men with PC) (Abdalla et al., 1998a-b; Vijayakumar et al., 1998), due evidently 
to greater PSA secretion per unit prostate volume by African-American men (Fowler et 
al., 1999). Although a substantial fraction of “slightly” elevated PSA levels (between 4 
and 10 ng/mL) is attributable to BPH or infection, “highly elevated” PSA levels (≥20 
ng/mL) typically indicate a strong likelihood of localized or metastatic PC, with 80 to 
90% positive predictivity and >99% specificity (Määttänen et al., 2001; Gerstenbluth et 
al., 2002; Smith et al., 2004). Likewise, a PSA measure < 4.0 ng/mL often considered 
within the “normal” range is actually associated with about at 15% of later PC diagnosis 
(Thompson et al., 2004). 
 
 
 
Report Body 
 
Objective/Hypotheses:  The study goal is to broaden the scope and power of a 
ground-breaking study of potential association between dietary HA exposure and 
screening indicators of PC risk in African-American men by adding a newer %fPSA test 
to the PSA/DRE protocol now being used.  We hypothesize 1) that the added %fPSA 
test will increase PC detection in our study population, and 2) that the combined 
screening, follow-up diagnostic and dietary survey data obtained will reveal a positive 
association between estimated HA intake and screening and diagnostic indicators of 
increased PC risk in our African American study population. 
Specific aims:  Our aims are to 1) Add a newer %fPSA test to PSA and DRE screens 
being done in a current study of potential associations between HA and PC in Oakland, 
California, area African-American men. 2) Assess potential increased rate of PC 
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identified by including the %fPSA test with PSA and DRE results in light of clinical 
follow-up diagnoses obtained.  3) Use PSA-related and DRE test results, together with 
corresponding follow-up diagnostic and dietary survey data, to assess the potential 
association of HA-related exposure factors and increased PC risk in African-Americans. 
Study Design:  For aim 1, 400 participants are being solicited from an already-
established network of churches, clinics and additional African-American community 
groups in the Oakland, CA, area.  Detailed data on diet and meat consumption are 
being obtained by in-person interviews using established questionnaires, each followed 
by PSA-related and DRE screening tests, and follow-up diagnosis—a study design that 
avoids potential bias due to prior participant/investigator knowledge of PC status.  Aims 
2 and 3 will be accomplished by statistical data analysis, with aim 3 supported by 
incorporation of similar (other than %fPSA) data obtained for an additional 300 
participants through our ongoing parallel NIH-funded study. Our focus on African-
Americans provides needed study power, in view of the greater PC risk faced by this 
specific group. 
 
 
Progress in Relation to Work Plan 
 
Work Plan Summary 
A total of 392 participants were accrued in an ongoing NIH-funded study through 
December 2004 using dietary interviews, a digital rectal exam (DRE), and a standard 
prostate serum antigen (PSA) blood test.  The DOD Prostate Cancer Research 
Program support has added a second PSA-related test— the “percent-free PSA” 
(%fPSA) test—to the protocol already applied to 82 additional participants as of 
December 2005, and will provide for 318 additional study participants through January 
of 2008, for whom blood samples will be used for both a PSA and a %fPSA test, over a 
two-year period, together with the dietary interview and DRE.   
 
Delayed Receipt of Funds and HSRRB Approval of Human Subjects Protocol 
 Initiation of the study was delayed due to delayed receipt of DOD funds by 
Lawrence Livermore National Laboratory (LLNL).  Due to contract language 
negotiations, funds arrived at LLNL approximately four months after the official start 
date of the project (Jan. 5, 2005).  A further start-up delay occurred due to delayed 
receipt of U.S. Army Human Subjects Research Review Board (HSRRB) approval of the 
study human subjects protocol, which had already received approval by the other three 
Institutional Review Boards (IRBs) involved in this study (those of LLNL, the University 
of California San Francisco Medical School, and the Summit Alta Bates medical Center 
in Oakland, CA).  A draft human subjects protocol was submitted to the HSRRB in 
December of 2004, but HSRRB approval was not obtained until mid-May of 2005. 
 
 In view of the delayed start-up of the project, a no-cost 6-month extension of this 
project (through June 31, 2008) will be requested circa August 2007 from the DOD 
grant manager for this project (Dr. L.C. Mishra, 301-619-7782). 
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Study Progress (indicated below in bold) 
 
 Note that, considering the ~6-month delay in start-up and anticipated 
corresponding performance-period extension, the time point of this reporting period in 
the study is approximately Month 6 of an anticipated 3-year performance period. 
 
Task 1. Add %fPSA test to the standard PSA blood test and DRE being done in a 
current study protocol to assess  potential HA/PC associations in Oakland-area African 
American men (Months 1-27). Initiated as of June 15, 2005. 
 
 
1.A.  Obtain IRB approvals for modified study protocol (Months 1-3).  
Accomplishment of this task will be facilitated by the established protocol currently being 
used in the ongoing parallel NIH-funded study; approvals will be obtained for a 
modification of this protocol to add the %fPSA test to the PSA and DRE screens 
currently being used, to extend the study termination date by one year (through January 
2008), and to increase the number of participants by 300 to a study total of 700.  
Completed in May of 2005. 
 
1.B. Implement combined PSA-test protocol (PSA + %fPSA) for a total of 400 
African American men screened at the Summit Alta-Bates MCEPC clinic in Oakland, 
California (Months 4-27).  The %fPSA, PSA and DRE procedures to be used are all 
clinical procedures now performed routinely at the study clinic (Markstein Cancer 
Education and Prevention Center, Alta Bates Summit Medical Center, Oakland, CA). 
Initiated as of June 15, 2005.   
 
1.C.  We will interview study subjects and edit dietary questionnaires for all study 
subjects, to include:  
 
1.C.1.  200 participants, comprising 100 DOD-funded participants plus 100 
participants funded by NIH, all to be screened during Months 3-15 A total of 82 (of 400) 
were completed as of December 31, 2005 (~16 more in January of 2006). 
 
1.C.2.  200 additional DOD-funded participants will be screened during Months 
16-27. Yet to be done. 
 
1.C.3.  For all participants to be screened in this study, previously developed 
dietary survey questionnaires will be used in the same manner they are being used in 
our ongoing corresponding NIH-funded research study (see Questionnaires, Surveys & 
Clinical Protocols). Initiated as of June 15, 2005. 
 
 
Task 2. Assess improvement in PC sensitivity and selectivity by addition of %fPSA 
test to the standard PSA test based on PSA-related test results and follow-up diagnoses 
in our African American study participants (Months 18-36). All yet to be done. 
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2.A. Data analysis methods to be used will be identical to those in use for the 
current related NIH-funded study (see Questionnaires, Surveys & Clinical Protocols) 
 
2.B.  Preliminary statistical analyses will be conducted during Months 18-27 
 
 2.C. Final statistical analyses will be conducted during Months 27-36 
 
 
Task 3. Use Combined PSA-related test results, together with dietary survey data, 
to assess the potential association of HA-related exposure factors and increased PC 
risk in African Americans (Months 13-36). 
 
 
3.A. Data analysis methods to be used will be identical to those in use for the 
current related NIH-funded study. Analysis of initial data set (n = 392) obtained 
using the original protocol for NIH-funded work is described below.  These 
results set the stage for follow-up analyses that will add new data involving 
%fPSA test results. 
 
3.B.  Preliminary statistical analyses of the statistical validity of Study Hypotheses 
1 and 2 will occur during Months 18-27. Yet to be done. 
 
3.C. Final statistical analyses of the statistical validity of Study Hypotheses 1 and 
2, as well as manuscript preparation, will occur during Months 27-36. Yet to be done. 
 
3.D. We will also, as feasible, test the validity of Study Hypothesis 2 using 
combine DOD-funded data set (n = 400) with NIH-only-funded data set (n = 300), during 
Months 27-36. Yet to be done, except for analysis of initial data set (n = 392) 
obtained using the original protocol for NIH-funded work, as described below.  
These results set the stage for follow-up analyses that will add new data involving 
%fPSA test results. 
 
 
 
Preliminary Progress (Interim analysis of NIH-funded data set) 
 
In accordance with IRB-approved human subjects protocols, an ongoing clinic-
based prospective study has enrolled male African-American volunteers from the 
Oakland, CA, area in accordance with the following inclusion criteria: (1) African-
American men between 40 and 70 years old; (2) no previous PC diagnosis or medical 
condition preventing or interfering with study participation; and (3) written informed 
consent. Participation was facilitated by a $30 incentive payment, as well as by >10 yr 
of previous PC-related community outreach undertaken by the study clinic (the 
Markstein Cancer Education and Prevention Center at Summit Alta Bates Medical 
Center in Oakland, CA). After providing written informed consent, each participant 
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completed a PC-screening medical questionnaire, answered general and meat-
/cooking-specific dietary questions, and was then provided free PC screening 
comprising a PSA blood test, and a digital-rectal exam by a board-certified urologist). 
General dietary intakes over the previous year were estimated using the Block-2000 
questionnaire with portion-size arrays standardized food models to help each participant 
select portion sizes (Block et al., 1986). Meat-/cooking-specific dietary information 
pertaining to the previous year was obtained using an additional questionnaire including 
a validated set of standard meat-doneness descriptors and corresponding set of 
photographic meat-doneness descriptors (Alavanja et al., 1996; Sinha et al., 1998b-c). 
All dietary questionnaire were data were obtained by in-person interviews administered 
by trained dietary interviewers. 
 
Combined survey data were used as previously described (Bogen and Keating, 2001) to 
estimate annual average dietary PhIP intake from all sources by each participant. Total 
and basal energy intake (in kcal per kg body weight) was estimated for each study 
participant by methods previously described (Bogen and Keating, 2001). Standard 
methods were used to assess the significance of linear associations and (where 
specifically mentioned) point-wise outliers therefrom, and to assess Pearson product-
moment correlations (Draper and Smith, 1981; Selvin, 1995). Approximate significance 
of differences in mean HA-intake rates were compared by T-tests, using Welch’s T-test 
in case of unequal variances as assessed by corresponding F-tests (Kendall and Stuart, 
1979). Odds ratio (OR) and corresponding 95% confidence interval (CI) estimates were 
obtained by numerical maximum-likelihood procedures, and corresponding chi-square 
tests for trend, with or without adjustment for specified factors, was performed using 
standard methods (Breslow and Day, 1987). Difference between empirical cumulative 
mass functions (cmfs) was assessed by Kolmogorov 2-sample (K2S) test (Wilcox, 
1997). All calculations were done using Mathematica 5.1® software (Wolfram, 1999). 
 
Data on 392 African-American men who participated in this study are summarized in 
Table 1. Corresponding estimated average daily intakes of specific meats and of total 
PhIP are summarized in Figure 1. The empirical distribution of estimated daily intakes of 
PhIP from all meats (“total PhIP”) (Figure 1, rightmost curve) has geometric and 
arithmetic mean values of 9.6 and 17 ng kg-1 d-1, respectively, and a geometric standard 
deviation of 3.34. Ratios of total to basal daily intake rates of energy per unit body 
weight (Efood:Ebasal, unitless) estimated for this study population (not shown) have an 
arithmetic mean (±1 standard error of the mean) of 1.57 (± 0.046) not significantly 
different (p = 0.51) from the value of 1.6 expected for reference adult men (Bogen and 
Keating, 2001). All but approximately 11% of the inter-individual variance in PhIP 
intakes estimated using all meat- and cooking-method-specific doneness information 
was found to be explained by corresponding estimates conditioned on meat- and 
cooking-method-specific PhIP concentrations averaged over all participants, i.e., by 
factors (such as intake rates for specific meats cooked using specific methods) 
unrelated to differences in individually reported doneness preferences. 
 
Estimated daily intakes of total PhIP were found to explain ~32% of observed inter-
individual variance in corresponding estimated intakes of saturated fat per unit body 
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Table 1.  Estimated mean HA intakes by all 21,858 CSFII participants who consumed HAs, by 
age group. 
Variablea Value(s) n 
Mean 
39 to 50 115 47.2 
51 to 60 216 54.6 
61 to 70 61 63.6 
Age (y) 
All 392 53.9 
Weight (kg) 54.4 to 163 392 85.7c 
<30 317 25.2 
≥30 75 33.9 BMI (kg cm-2) 
18.4 to 46.0 392 26.9 
< 2 328 0.79 
2 to <4 42 2.7 
4 to <10 10 5.5 
10 to <20 7 14 
PSA (ng/mL) 
≥20 5 47 
  PSA<4 PSA≥4a 
Normal 233 15 
BPH 108 4 DRE 
Suspiciousa 12 3 
No 333 15 
Family historyb 
Yes 37 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes 
a BMI = body mass 
index; DRE = digital 
rectal exam; 
Suspicious = 
abnormal DRE 
result leading to 
medical referral; 
Normal = no 
urinary, BPH or 
other symptoms. 
Each abnormal 
PSA result (≥4.0 
ng/mL) triggered 
referral for medical 
follow-up. 
b Family history = 
self reported 
brother(s) and/or 
father diagnosed 
with prostate 
cancer. Association 
of positive family 
history with PSA ≥ 
4 ng/mL is 
significantly positive 
by 2-tail Fisher 
exact test (p = 
0.013). 
c Weight median 
(interquartile range) 
= 83.9 (74.8 to 
95.3) kg. 
 
Figure 1.  Cumulative distributions of estimated PhIP 
intake by meat type for the study population of 392 
Oakland, CA-area African-American men.  Curves with 
increasing boldness denote the following meat types 
(and corresponding % of total estimated intake): burger 
(15%), other beef (14%), chicken (61%), and total 
(100%). 
Figure 2.  Saturated fat (g/kg-d) intake estimated by 
FFQ vs. PhIP intake estimated by the LLNL Meat 
questionnaire for 392 Oakland, CA-area African-
American men (open points).  Linear regression shown 
(solid line) indicates a significantly positive association. 
A single point (closed circle) determined to be an outlier 
(p < 10-5 by F test) was excluded from the regression 
analysis. 
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Table 2.  Association of PhIP intake with elevated PSA in African-American men ≥ 55 years old.  
Adjustment or 
restrictiona      . 
PSA ≥ 20 
ng/mLb     
    Ave. PhIP intakea 
   PRa     (ng kg-1 d-1) m n ORa 95%LCLa 95%UCLa ptrenda 
All data       
    0-50:              4.6 0 83 1    
    >50-70:       14.4 1 33 7.6 0.47 200  
    >70-85:       24.0 0 25 – – –  
   >85-100:     47.7 4 26 32. 3.2 720 0.00020 
Adj. for FH   
    (same as above) (m, n, ORs, LCLs and UCLs approx. unchangedc) 0.00039 
FH –       
    0-50:              4.6 0 76 1    
    >50-70:       14.4 1 27 8.5 0.52 220  
    >70-85:       24.0 0 22 – – –  
   >85-100:     47.7 2 22 18. 1.5 430 0.016 
FH +       
    0-50:              4.6 0 22 1    
    >50-70:       14.4 0 9 – – –  
    >70-85:       24.0 0 6 – – –  
   >85-100:     47.7 2 7 18. 1.4 540 0.0067 
Adj. for SatFat       
    0-50:              4.6 0 83 1    
    >50-70:       14.4 1 33 4.1 0.25 110  
    >70-85:       24.0 0 25 – – –  
   >85-100:     47.7 4 26 32. 3.2 720 0.0024 
Adj. for KCAL       
    0-50:              4.6 0 83 1    
    >50-70:       14.4 1 33 – – –  
    >70-85:       24.0 0 25 4.0 0.24 110  
   >85-100:     47.7 4 26 32. 3.2 720 0.0011 
       
a PR = percentile range; FH = family history (self reported brother/s and/or father diagnosed with prostate cancer; 
SatFat = daily saturated fat intake per kg body weight; KCAL = total energy intake per kg body weight.  Trend 
analyses adjusting for SatFat or KCAL were each done using the adjustment variable dichotomized at its median 
value.  
b m = number with PSA ≥ 20 ng/mL among n total participants included in the analysis. 
c At mean PhIP-intake level 14.4 ng kg-1 d-1, OR (95%CL) = 8.5 (0.52, 220). 
Figure 3.  Cumulative distributions of PSA 
measured in 392 Oakland, CA-area African-
American men who did (FH +), vs. who who did not 
(FH –), report a father and/or brothers diagnosed 
with prostate cancer. 
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weight (Figure 2). Similar of greater levels of positive correlation were observed 
between estimated total PhIP intake and energy-intake ratio (Efood:Ebasal) (R2 = 0.26), 
total energy intake (Efood) (R2 = 0.27), total meat intake (g kg-1 d-1) (R2 = 0.68), and 
between estimated intakes of total energy and saturated fat (R2 = 0.84) and Efood:Ebasal 
(R2 = 0.97). PSA measures were found to have a weak positive association with 
participant age that attained statistical significance for all measures < 4 ng/mL (R2 = 
0.051, p = 0.000012), but not for all measures ≥ 4 ng/mL (R2 = 0.035, p = 0.41). All PSA 
measures ≥ 20 ng/mL were obtained for participants between 55 and 65 years old. 
 
Figure 3 summarizes PSA measures among participants reporting vs. not reporting a 
close relation (a father and/or brother) with PC. PSA measures were found to be 
significantly greater among those reporting such a family history (p = 0.023 by K2S 
test), particularly when the comparison is restricted to the upper quartile of PSA 
measures in each family-history category (p = 1.9 × 10-6 by K2S test). Although positive 
family history was found to be significantly positively associated with elevated PSA 
defined as any measure ≥ 4 ng/mL (p = 0.013 by 2-tail Fisher exact test, Table 1), this 
was not the case using the following alternative elevated-PSA criteria: ≥ (vs. <) 10 
ng/mL (p = 0.28), ≥ (vs. <) 15 ng/mL (p = 0.099), ≥ (vs. <) 20 ng/mL (p = 0.20), or ≥ 20 
vs. < 4 ng/mL (p = 0.17). 
 
Because estimated PhIP intakes were found to have a highly skewed distribution 
(Figure 1), association between PhIP intake and highly elevated PSA (≥ 20 ng/mL) 
status was investigated using PhIP-intake bin boundaries defined by the 50th, 70th, and 
85th percentile values of the empirical intake distribution. Thus categorized, PhIP-intake 
level was found to be significantly positively associated with highly elevated PSA status, 
compared to this status among participants in the lowest half of estimated PhIP intakes, 
with or without single-variable adjustment for father/brother family history of PC, 
saturated fat intake, or total energy (corresponding p-values for trend of ptrend = 0.014 
for SatFat adjustment, ptrend ≤ 0.003 for all other tests). As mentioned, all highly elevated 
PhIP measures occurred in men within a fairly narrow age range (55 to 65 years old). In 
just the men ≥ 55 years old, PhIP-intake level was found to be even more significantly 
positively associated with highly elevated PSA status, compared to this status among 
this subset of participants who also were in the lowest half of estimated PhIP intakes, 
with or without single-variable adjustment for father/brother family history of PC, 
saturated fat intake, or total energy (Table 2). In particular, this association among men 
in the highest 15% compared to those in the bottom 50% of estimated PhIP intakes was 
found to have a maximum-likelihood odds ratio (and corresponding 95% confidence 
limits) of 32 (3.6, 720), with a corresponding p-value for trend of ptrend = 0.00020. 
Adjustment for father/brother family history of PC, saturated fat intake, or total energy 
yielded identical odds-ratio estimates, and only slightly greater estimates of ptrend (Table 
2). 
 
A generally similar significant pattern of positive association was also observed between 
estimated PhIP intake and men with highly elevated PC risk defined as either PSA ≥ 20 
ng/mL or a “suspicious” abnormal DRE result leading to medical referral (data not 
shown). Such suspicious DRE results were obtained among a ~4-fold greater fraction (3 
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of 12) participants with mildly elevated PSA (≥ 4.0 ng/mL) than among (12 of 370 of) 
those with PSA < 4.0 ng/mL—a difference that is not statistically significant (p = 0.11 by 
2-tail Fisher exact test) perhaps due to study size. Suspicious DRE results were not 
obtained for any participant with a PSA measure ≥ 20 ng/mL.  Separate trend analyses 
done to assess for positive association between highly elevated PSA and (either 
quintiles, or {50, 70, 85}th percentile intervals of) either saturated fat intake, total energy 
intake, or body mass index, did not yield statistically significant trend-test results with or 
without adjustment for PhIP intake (ptrend > 0.10 for each of 12 separate tests). 
 
The interim data obtained from the ongoing study described are consistent with the 
hypothesis that a PSA- related, and a combined PSA- and DRE-related, screening 
indicator of highly elevated PC risk is significantly positively associated with estimated 
dietary exposure to PhIP. Although this conclusion remains tentative in view of the fairly 
small number of men involved in this prospective study so far, it is supported by the 
consistency of the pattern of results found, their level of statistical significance, and the 
significant positive association observed between highly elevated PSA and a positive 
father/brother history of PC consistent with previous studies that clearly have linked this 
factor to elevated PC risk (see Introduction).  
 
An apparent contradiction between results obtained in this study and those of that 
comparing HA intake (primarily from cooked lamb) and PC risk in New Zeeland men 
(including 317 PC cases and 480 age-matched controls) studied by Norrish et al. 
(1999)—who found no significant PhIP-related associations involving PC—is easily 
explained. The lower bound on individual-average daily PhIP intake (224 ng/d) that 
study used in its top exposure quartile that was about 12-fold lower than the lower 
bound (of about 2680 ng/d) of the top 15% (the highest category) of PhIP exposures 
estimated for the East San Francisco Bay area African-American men in the present 
study. If the dose-response for PhIP-induced elevation of PC risk were assumed to be 
linear no-threshold, linear extrapolation from significantly elevated OR estimates ≥ 2.2 
or 3.2 obtained in the present study down to PhIP exposure levels used in the Norrish et 
al. (1999) study would require the latter study to be able to detect elevated OR values 
as low as about 1.2 or 1.3 in order to have detected a significant PhIP-related 
association with 95% confidence at 80% statistical power. In contrast, exact evaluation 
of non-central hypergeometric distributions (Zelterman, 1999) corresponding to the 
Norrish et al. (1999) study design indicate it could only detect an OR as low as about 
1.8 with 95% confidence at 80% power for comparisons involving its lowest vs. highest 
exposure quartiles. Moreover, the empirical relation between mutagenic and 
carcinogenic potencies of genotoxic rodent-carcinogen chemicals, such as PhIP, 
suggests that the low-dose dose-response for cancer induction by such chemicals is 
likely to be sublinear in general (Bogen, 1993), which implies that the Norrish et al. 
(1999) design had even less power to detect elevated PC risk due to PhIP exposure 
levels studied. 
 
Ideally, a prospective study accumulates definitive diagnostic data together with data on 
exposure- or treatment-related variables of interest. A key limitation to interpretation of 
data obtained in this study so far is thus that, despite ongoing work to obtain 
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corresponding follow-up diagnostic data, a PC diagnosis is not yet (and for some, may 
never be) available for all participants who received either positive or highly elevated PC 
screening results or who received a “suspicious” DRE leading to medical referral. 
Compared to a case-control design, the prospective design used in this ongoing study 
has the advantage of being double blind, insofar as PC screening results analyzed are 
in each case known neither by the participant nor by study investigators until after each 
participant provides dietary survey data. This design eliminates potential bias (e.g., in 
participants’ self-reported cooking preferences) associated with knowledge of PC-
screening results or PC status, which is important in view of evidence that prior 
knowledge of cancer-related status can affect dietary recall and so induce significant 
differential misclassification (Wilkens et al., 1992).  
 
Summary of Interim Results 
 To investigate the hypothesis that PhIP exposure increases PC risk, an ongoing 
prospective clinic-based study has compared PC-screening outcomes with survey-
based estimates of dietary PhIP intake by 40- to 70-year-old African-American men in 
the Oakland, CA, area.  Participants with no prior PC diagnosis, recruited through a 
cancer education center/screening clinic, complete food-frequency and meat-
cooking/consumption questionnaires, and have a prostate serum antigen (PSA) test and 
digital-rectal exam.  Preliminary results for 392 participants indicate that mean (±1 SD) 
daily intake of PhIP, the major HA found in cooked meats, in this group is 17 (±17) ng 
kg-1 d-1, which is ~2-fold (and ~3-fold) greater than a national estimate of mean PhIP 
intake for African-American (and white U.S.) men of similar age.  In the present study, 
estimated PhIP intakes were found to be attributable mostly (61%) to chicken and 
positively associated (R2 = 0.32, p ~ 0) with estimated saturated fat (SF) intake 
(previously hypothesized to be a key environmental PC-risk factor).  A conditional 
maximum-likelihood odds ratio, OR, (and 95% confidence limits) of 32 (3.2, 720) for 
highly elevated PSA ≥20 ng/mL was observed in the highest 15% compared to the 
lower 50% of estimated daily PhIP intakes (≥30 vs. ≤10 ng kg-1 d-1) by men 55+ years 
old, with a p-value (ptrend) of 0.00020 for a corresponding chi-square test for trend done 
across these and two additional PhIP-intake groups.  This positive trend persisted after 
separate adjustments for self-reported family (brother or father) history of PC (FH), SF 
intake, and energy intake (ptrend = 0.00039, 0.0024, and 0.0011, respectively).  PSA 
measures were found (by Kolmogorov 2-sample tests) to be significantly higher in 
African-American men reporting a positive FH in this study (p = 0.023), particularly for 
those among the highest PSA-measure quartile in each FH group (p < 10-5).  These 
preliminary results are consistent with a positive association between PhIP intake and 
highly elevated PSA levels, supporting the hypothesis that diet and food preparation 
interventions may help reduce PC risk in African-American and perhaps other groups.  
Current and planned related work involving additional study participants, from whom an 
additional PC screening measure (%fPSA) is being obtained, will increase the power of 
this study to detect and investigate PhIP-related effects on PC risk in the African-
American men studied. 
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Key Research Accomplishments  
 
 The NIH-funded P01 work that set the stage for the present expanded study has 
accomplished the two specific aims it sought to address.  We successfully applied 
methods for estimating HA concentrations in cooked meats based on individually 
expressed data on meat-specific intakes, cooking methods and doneness preferences 
to estimate daily PhIP intakes, and we have found these intake estimates to be 
positively associated with screening indicators of highly elevated PC risk in a 
prospective clinic-based PC screening study involving nearly 400 African-American men 
in the San Francisco East Bay area. The observed positive association, which was most 
significant among men 55 to 70 years of age (ptrend = 0.00020), remained statistically 
significant after adjustments for saturated fat intake, total energy intake and self-
reported father/brother history of PC. 
 
Future work will continue to accrue participants using the same basic study 
design, except insofar as to expand the screening indicators used to predict PC status 
to include the %fPSA test, and to assess whether PhIP-related associations pertain to 
combined screening indicator data using a larger study population.  In so doing, this 
study will continue to help define the potential value of improved screening and 
dietary/behavioral intervention to reduce PC risk, namely, prevention of PhIP intake by 
avoiding overcooked meats. 
 
 
Reportable Outcomes  
 
Abstracts/Posters 
 
Bogen, K, W Baker, J Chan, D Nelson, E Holly, G Keating, L Paine, and J Felton. 2005. 
Prostate cancer screening and dietary HA exposure in African-Americans. UCRL-
POST-211476. Poster presented at the University of California Davis Health System 
Future Fair, May 5, 2005, UC Davis Medical Center, Sacramento, CA. 
 
KT Bogen, GA Keating, EA Holly, J Chan, L Paine, EL Simms, DO Nelson, and J 
Felton. 2005. Prostate Serum Antigen levels and dietary heterocyclic amines in 
African Americans: A prospective clinic-based study. Abstract of poster accepted for 
presentation at the 97th Annual Meeting of the American Assoc. for Cancer 
Research, April 1-5, 2006, Washington, DC. UCRL-ABS-217085. Lawrence 
Livermore National Laboratory, Livermore, CA. 
 
 
Manuscripts 
 
Keating, GA, and K Bogen. 2006. Development of a meat frequency questionnaire for 
use in diet and cancer studies. Submitted to J. Am. Dietetic Assoc. UCRL-JRNL-
208025, Lawrence Livermore National Laboratory, Livermore, CA. 
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Bogen KT, GA Keating, JM Chan, EA Holly LJ Paine, EL Simms, and DO Nelson. 2006. 
Highly elevated PSA and dietary PhIP intake by African Americans: Interim results 
from a prospective clinic-based study. Prepared for submittal to J. Expos. Anal. 
Environ. Epidemiol. [included in the Appendix of this report] 
 
 
 
Conclusion 
Prostate cancer (PC) is the second leading cause of male U.S. cancer deaths, 
with African-Americans having the highest rate of PC mortality worldwide, as well as 
more abnormal results from screening tests that correlate with current or eventual PC.  
A 3-year prospective clinic-based study is studying the performance of current (PSA 
and DRE) vs. (% free PSA) clinical biomarkers of PC risk in 400 African-American men 
50 to 70 years of age who undergo PC screening in Oakland, CA (East Bay San 
Francisco area), as well as possible association of PC screening results for these men 
with their dietary exposures to the cancer-causing heterocyclic amine, 2-amino-1-
methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) that forms when meat is cooked.  This 
study expands an ongoing NIH-funded study (by the same research team) to add a new 
%-free-PSA test, results of which will be compared with PSA/ DRE results and PhIP 
exposures estimated by dietary interviews.  For 392 men studied under the NIH 
protocol, an odds ratio (95% CL) of 32 (3.2, 720) for highly elevated PSA (≥20 ng/mL) 
was observed in the highest 15% vs. the lower 50% of estimated daily PhIP intakes.  
Approximately 100 additional men have completed participation in the expanded 
NIH/DOD-supported study. 
 
Future work will continue to accrue participants in this study, expand the 
screening indicators used to predict PC status to include the %fPSA test, and to assess 
whether PhIP-related associations pertain to combined screening indicator data using a 
larger study population.  In so doing, this study will continue to help define the potential 
value of improved screening and dietary/behavioral intervention to reduce PC risk, 
namely, prevention of PhIP intake by avoiding overcooked meats. 
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ABSTRACT 
 
 African American (AA) men, who compared to Caucasians die nearly twice as much from prostate cancer 
(PC), also take in about twice as much of the predominant U.S. dietary heterocyclic amine, 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP), which occurs primarily in well-cooked chicken and beef.  To investigate the 
hypothesis that PhIP exposure increases PC risk, an ongoing prospective clinic-based study has compared PC-
screening outcomes with survey-based estimates of dietary PhIP intake by 40- to 70-year-old AA men in the 
Oakland, CA, area.  Participants with no prior PC diagnosis, recruited through a cancer education center/screening 
clinic, complete food-frequency and meat-cooking/consumption questionnaires, and have a prostate serum antigen 
(PSA) test and digital-rectal exam.  Preliminary results for 392 participants indicate that mean (±1 SD) daily intake 
of PhIP, the major HA found in cooked meats, in this group is 17 (±17) ng kg-1 d-1, which is ~2-fold (and ~3-fold) 
greater than a national estimate of mean PhIP intake for AA (and white U.S.) men of similar age.  In the present 
study, estimated PhIP intakes were found to be attributable mostly (61%) to chicken and positively associated (R2 = 
0.32, p ~ 0) with estimated saturated fat (SF) intake (previously hypothesized to be a key environmental PC-risk 
factor).  A maximum-likelihood odds ratio, OR, (and 95% confidence limits) of 32 (3.2, 720) for highly elevated 
PSA ≥20 ng/mL was observed in the highest 15% compared to the lower 50% of estimated daily PhIP intakes (≥30 
vs. ≤10 ng kg-1 d-1) by men 55+ years old, with a p-value (ptrend) of 0.00020 for a corresponding chi-square test for 
trend done across these and two additional PhIP-intake groups.  This positive trend persisted after separate 
adjustments for self-reported family (brother or father) history of PC (FH), SF intake, and energy intake (ptrend = 
0.00039, 0.0024, and 0.0011, respectively).  PSA measures were found (by Kolmogorov 2-sample tests) to be 
significantly higher in AA men reporting a positive FH in this study (p = 0.023), particularly for those among the 
highest PSA-measure quartile in each FH group (p < 10-5).  These preliminary results are consistent with a positive 
association between PhIP intake and highly elevated PSA levels, supporting the hypothesis that diet and food 
preparation interventions may help reduce PC risk in AA and perhaps other groups. 
 
Key Words: Age, cancer, cooking, meat mutagens, energy, meat, prostate, race, sex, variability 
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Introduction 
 Heterocyclic amines (HAs) are potent mutagens formed in meats, chicken and fish as it is cooked to higher-
doneness levels by heat-intensive cooking methods (Thompson et al., 1987; Keating et al., 1999, 2000).  HAs also 
cause cancer at a variety of sites in multiple bioassay animal species/strains/sexes, as well as at multiple sites within 
many of species/strains/sexes tested (Bogen, 1994).  A predominant HA found in cooked and particularly in well-
done chicken and beef is 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) (Felton et al., 1984, 1986; 
Felton and Knize, 1990a-b; Sinha et al., 1995).  Dietary exposure to PhIP has been shown to induce colon, intestinal 
and mammary adenocarcinomas in rats (Ohgaki et al., 1986; Ochiai et al., 1991; Ito et al., 1991; Ito et al., 1997; 
Ghoshal et al., 1994), as well as prostate cancer in rats (Shirai et al., 1997,1999).  HAs are metabolically activated 
by P450 and N-acetyltransferase enzymes to activated forms that bind covalently to (among other targets) DNA in 
tissues (including in prostate) where HAs induce cancer in rats (Thorgeirsson et al., 1983; Thorgeirsson, 1984; 
Rosenkranz and Mermeistein, 1985; Sato et al., 1986; Kato and Yamazoe, 1987; Snyderwine and Battula, 1989; 
McManus et al., 1990; Turesky et al., 1991; Davis et al., 1993; Kaderlik et al., 1994a-b; Takahashi et al., 1998; 
Schut and Snyderwine, 1999; Gooderham et al., 2002).  In male lacI trangenic rats, a diet containing 200 ppm PhIP 
was shown to be highly mutagenic in prostate tissue (Stuart et al., 2000).  In cultured human prostate tissue and 
primary prostate cells, PhIP is metabolically activated to mutagenic forms that covalently bind to and damage DNA 
(Williams et al., 2000; Lawson and Kolar, 2002; Martin et al., 2002; Di Paolo et al., 2005). 
 In the U.S., prostate cancer (PC) is a leading cause of cancer death among men, with African Americans 
having the highest age-specific prostate cancer rate in the world, and a >2-fold higher rate of mortality for PC than 
white men in the U.S.(Miller et al., 1996; Robbins et al., 1998; Hsing et al., 2000).  Although family (particularly 
father/brother) history of PC is clearly linked to substantially elevated PC risk (Schuurman et al., 1999; Hemminki 
and Czene, 2002; Zeegers et al., 2003; Hemminki and Chen, 2005) and a human-PC-specific chromosome 
translocation has been identified (Tomlins et al., 2005), there is (as for most other cancers) no evidence for a 
predominant heritable factor for PC.  Racial-ethnic differences in levels of testosterone-related hormones and related 
genetic controls on hormone-induced prostate growth have been hypothesized to explain or contribute to 
corresponding racial-ethnic differences in PC risk, but their role remains unclear (Ross et al., 1998; Pettaway, 1999; 
Hsing, 2001).  Even if hormonally mediated background processes do affect PC risk, dietary exposures to genotoxic 
Rev. 1.1:  13 Jan 2006 
 
28 
 
HA carcinogens may act independently or interact synergistically with such hormonal processes to further modify 
PC risk. 
 Substantial geographical variations in PC incidence indicate the importance of one or more dietary or other 
environmental factors (Minami et al., 1993; Mettlin, 1997; Angwafo, 1999).  Dietary intake of animal or saturated 
fat is the environmental factor most consistently linked to significantly increased PC risk in previous studies, 
particularly among African-American men, though these associations appear too weak to explain more than a small 
fraction of observed racial-ethnic differences in PC risk (Whittemore et al., 1995; Hayes et al., 1999; Kolonel et al., 
1999; Daniels et al., 2004), as also appears to be the case for other environmental/dietary factors examined such 
calcium, cruciferous vegetables, vitamin D, UV from sunlight, lycopene, and body size (Giovannucci et al., 1997, 
1998; Cohen et al., 2000; Chan and Giovannucci, 2001a-b; Kristal and Lampe, 2002; Bodiwala et al., 2003).  
Because cooked-meat intake is positively associated with total saturated-fat intake (USDA, 1998), previous studies 
that focused on animal or saturated fat per se could have estimated effects due largely or entirely to meat-related HA 
intakes. 
 Consumption of cooked meats and associated HAs have been linked to increased risks of colorectal 
adenoma/adenocarcinoma and of cancer of the stomach, breast, lung and prostate (Mills et al., 1989; Shiffman and 
Felton, 1990; Gerhardsson de Verdier et al., 1991; Talamini et al., 1992; Lang et al., 1994; De Stefani et al., 1995; 
Ewings and Bowie, 1996; Probst-Hensch et al., 1997; Ward et al., 1997; Kampman et al., 1999; Norrish et al., 1999; 
Sinha et al., 1998a, 1999a-b; Zheng et al., 1998, 1999; Murtaugh et al., 2004), while fewer studies found no such 
associations (Lyon and Mahoney, 1988; Muscat and Wynder, 1994; Augustsson et al., 1999).  Positive studies 
include those in which HA exposure was quantified adjusting for factors expected to determine HA intake—namely, 
meat type, consumption frequency, cooking method, and cooking doneness.  A potential link between PhIP intake, 
in particular, and the elevated risk of PC experienced by African-American compared to Caucasian men is suggested 
by relatively greater levels of PhIP and its metabolites detected in urine sampled from the latter vs. the former group 
(Kidd et al., 1999), although urine analysis only provides a measure of PhIP exposure within 12-24 hours prior to 
sampling (Malfatti et al., 1999).  Such a link is also supported by studies using meat- and cooking-method-specific 
HA-concentration estimates from multi-laboratory sets of experimental cooking data (Keating and Bogen, 2001) to 
assess intakes of PhIP and other HAs by >20,000 U.S. (including >3,000 African-American) participants in the 
nationwide, stratified, random-sample U.S. Continuing Survey of Food Intakes by Individuals (CSFII) (USDA, 
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1993, 1998).  Analyzed by age-, sex, and race/ethnicity, these HA-exposure assessments found at all ages that 
African-American males consume on average at least twice as much PhIP (and total HA) per kg body weight per 
day as do U.S. Caucasian males, and that for both groups there is a significant positive (albeit small) correlation 
between estimated mean intakes of PhIP and those of saturated or total fat (Keating and Bogen, 2001; Bogen and 
Keating, 2001). 
 Although the study comparing HA intake (primarily from cooked lamb) and PC risk in New Zeeland men by 
Norrish et al. (1999) found no significant PhIP-related associations involving PC, that study did report a significant 
association between PC risk and consumption of beefsteak by higher cooking-doneness category (2-sided ptrend = 
0.008).  Several aspects of that study suggest it may have had limited power to assess potential associations between 
PC and HA or PhIP intake in the U.S.  The incidence of PC in New Zeeland is only half that of Caucasian men in 
the U.S. (Hsing et al. 2000).  Average meat (primarily lamb) consumption by subjects in the Norrish et al. study 
(~150 g/d) was well below that of U.S. Caucasian men (260 g/d) and very well below that of African-American men 
(304 g/d) (USDA, 1998; Table 10A).  Moreover, the minimum PhIP intake (224 ng/d) in the top exposure quartile of 
Norrish et al. study subjects was well below the estimated average PhIP intakes by U.S. Caucasian (390 ng/d) and 
by African-American (600 ng/d) men (Bogen and Keating 2001).   
 Periodic screening for plasma levels of Prostate-Specific Antigen (PSA) is useful for early detection of PC as 
well as benign prostatic hyperplasia (BPH) because PSA levels in serum are positively associated with age, prostate 
volume, and prostatic neoplastic disease (Carter et al., 1992; Oesterling et al., 1993; Etzioni et al., 1999).  
Significantly higher PSA levels are found in African-Americans than in whites, even after adjustment for age and 
prostate volume (in men without PC) and for PC grade and stage (in men with PC) (Abdalla et al., 1998a-b; 
Vijayakumar et al., 1998), due evidently to greater PSA secretion per unit prostate volume by African-American 
men (Fowler et al., 1999).  Although a substantial fraction of “slightly” elevated PSA levels (between 4 and 10 
ng/mL) is attributable to BPH or infection, “highly elevated” PSA levels (≥20 ng/mL) typically indicate a strong 
likelihood of localized or metastatic PC, with 80 to 90% positive predictivity and >99% specificity (Määttänen et al., 
2001; Gerstenbluth et al., 2002; Smith et al., 2004).  Likewise, a PSA measure < 4.0 ng/mL often considered within 
the “normal” range is actually associated with about at 15% of later PC diagnosis (Thompson et al., 2004).  The 
present study was conducted to assess the association between highly elevated PSA and estimated dietary exposure 
to PhIP. 
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Methods 
 Study design.  In accordance with IRB-approved human subjects protocols, an ongoing clinic-based 
prospective study has enrolled male African-American volunteers from the Oakland, CA, area in accordance with 
the following inclusion criteria: (1) African-American men between 40 and 70 years old; (2) no previous PC 
diagnosis or medical condition preventing or interfering with study participation; and (3) written informed consent.  
Participation was facilitated by a $30 incentive payment, as well as by >10 yr of previous PC-related community 
outreach undertaken by the study clinic (the Markstein Cancer Education and Prevention Center at Summit Alta 
Bates Medical Center in Oakland, CA).  After providing written informed consent, each participant completed a PC-
screening medical questionnaire, answered general and meat-/cooking-specific dietary questions, and was then 
provided free PC screening comprising a PSA blood test, and a digital-rectal exam by a board-certified urologist).  
General dietary intakes over the previous year were estimated using the Block-2000 questionnaire with portion-size 
arrays standardized food models to help each participant select portion sizes (Block et al., 1986).  Meat-/cooking-
specific dietary information pertaining to the previous year was obtained using an additional questionnaire including 
a validated set of standard meat-doneness descriptors and corresponding set of photographic meat-doneness 
descriptors (Alavanja et al., 1996; Sinha et al., 1998b-c).  All dietary questionnaire were data were obtained by in-
person interviews administered by trained dietary interviewers. 
 Data Analysis.  Combined survey data were used as previously described (Bogen and Keating, 2001) to 
estimate annual average dietary PhIP intake from all sources by each participant.  Total and basal energy intake (in 
kcal per kg body weight) was estimated for each study participant by methods previously described (Bogen and 
Keating, 2001).  Standard methods were used to assess the significance of linear associations and (where specifically 
mentioned) point-wise outliers therefrom, and to assess Pearson product-moment correlations (Draper and Smith, 
1981; Selvin, 1995).  Approximate significance of differences in mean HA-intake rates were compared by T-tests, 
using Welch’s T-test in case of unequal variances as assessed by corresponding F-tests (Kendall and Stuart, 1979).  
Odds ratio (OR) and corresponding 95% confidence interval (CI) estimates were obtained by numerical maximum-
likelihood procedures, and corresponding chi-square tests for trend, with or without adjustment for specified factors, 
was performed using standard methods (Breslow and Day, 1987).  Difference between empirical cumulative mass 
functions (cmfs) was assessed by Kolmogorov 2-sample (K2S) test (Wilcox, 1997).  Significance p-values ≤10-10 are 
reported as being ≈0.  All calculations were done using Mathematica 5.1® software (Wolfram, 1999). 
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Results 
 Data on 392 African-American men who participated in this study are summarized in Table 1.  Corresponding 
estimated average daily intakes of specific meats and of total PhIP are summarized in Table 2 and Figure 1.  The 
empirical distribution of estimated daily intakes of PhIP from all meats (“total PhIP”) (Figure 1, rightmost curve) 
has geometric and arithmetic mean values of 9.6 and 17 ng kg-1 d-1, respectively, and a geometric standard deviation 
of 3.34.  Ratios of total to basal daily intake rates of energy per unit body weight (Efood:Ebasal, unitless) estimated for 
this study population (Figure 2) have an arithmetic mean (±1 standard error of the mean) of 1.57 (± 0.046) not 
significantly different (p = 0.51) from the value of 1.6 expected for reference adult men (Bogen and Keating, 2001). 
 All but approximately 11% of the inter-individual variance in PhIP intakes estimated using all meat- and cooking-
method-specific doneness information was found to be explained by corresponding estimates conditioned on meat- 
and cooking-method-specific PhIP concentrations averaged over all participants, i.e., by factors (such as intake rates 
for specific meats cooked using specific methods) unrelated to differences in individually reported doneness 
preferences (Figure 3).   
 Estimated daily intakes of total PhIP were found to explain ~32% of observed inter-individual variance in 
corresponding estimated intakes of saturated fat per unit body weight (Figure 4).  Similar of greater levels of 
positive correlation were observed between estimated total PhIP intake and energy-intake ratio (Efood:Ebasal) (R2 = 
0.26), total energy intake (Efood) (R2 = 0.27), total meat intake (g kg-1 d-1) (R2 = 0.68), and between estimated intakes 
of total energy and saturated fat (R2 = 0.84) and Efood:Ebasal (R2 = 0.97). 
 PSA measures were found to have a weak positive association with participant age that attained statistical 
significance for all measures < 4 ng/mL (R2 = 0.051, p = 0.000012), but not for all measures ≥ 4 ng/mL (R2 = 0.035, 
p = 0.41).  All PSA measures ≥ 20 ng/mL were obtained for participants between 55 and 65 years old. 
 Figure 5 summarizes PSA measures among participants reporting vs. not reporting a close relation (a father 
and/or brother) with PC.  PSA measures were found to be significantly greater among those reporting such a family 
history (p = 0.023 by K2S test), particularly when the comparison is restricted to the upper quartile of PSA measures 
in each family-history category (p = 1.9 × 10-6 by K2S test).  Although positive family history was found to be 
significantly positively associated with elevated PSA defined as any measure ≥ 4 ng/mL (p = 0.013 by 2-tail Fisher 
exact test, Table 1), this was not the case using the following alternative elevated-PSA criteria:  ≥ (vs. <) 10 ng/mL 
(p = 0.28), ≥ (vs. <) 15 ng/mL (p = 0.099), ≥ (vs. <) 20 ng/mL (p = 0.20), or ≥ 20 vs. < 4 ng/mL (p = 0.17).   
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 Because estimated PhIP intakes were found to have a highly skewed distribution (Figure 1),  association 
between PhIP intake and highly elevated PSA (≥ 20 ng/mL) status was investigated using PhIP-intake bin 
boundaries defined by the 50th, 70th, and 85th percentile values of the empirical intake distribution.  Thus 
categorized, PhIP-intake level was found to be significantly positively associated with highly elevated PSA status, 
compared to this status among participants in the lowest half of estimated PhIP intakes, with or without single-
variable adjustment for father/brother family history of PC, saturated fat intake, or total energy (Table 3).  As 
mentioned, all highly elevated PhIP measures occurred in men within a fairly narrow age range (55 to 65 years old). 
 In just the men ≥ 55 years old, PhIP-intake level was found to be even more significantly positively associated with 
highly elevated PSA status, compared to this status among this subset of participants who also were in the lowest 
half of estimated PhIP intakes, with or without single-variable adjustment for father/brother family history of PC, 
saturated fat intake, or total energy (Table 4).  In particular, this association among men in the highest 15% 
compared to those in the bottom 50% of estimated PhIP intakes was found to have a maximum-likelihood odds ratio 
(and corresponding 95% confidence limits) of 32 (3.6, 720), with a corresponding p-value for trend of ptrend = 
0.00020.  Adjustment for father/brother family history of PC, saturated fat intake, or total energy yielded identical 
odds-ratio estimates, and only slightly greater estimates of ptrend (Table 4). 
 A generally similar significant pattern of positive association was also observed between estimated PhIP intake 
and men with highly elevated PC risk defined as either PSA ≥ 20 ng/mL or a “suspicious” abnormal DRE result 
leading to medical referral (Table 5).  Such suspicious DRE results were obtained among a ~4-fold greater fraction 
(3 of 12) participants with mildly elevated PSA (≥ 4.0 ng/mL) than among (12 of 370 of) those with PSA < 4.0 
ng/mL—a difference that is not statistically significant (p = 0.11 by 2-tail Fisher exact test) perhaps due to study 
size.  Suspicious DRE results were not obtained for any participant with a PSA measure ≥ 20 ng/mL. 
 Separate trend analyses done to assess for positive association between highly elevated PSA and (either 
quintiles, or {50, 70, 85}th percentile intervals of) either saturated fat intake, total energy intake, or body mass 
index, did not yield statistically significant trend-test results with or without adjustment for PhIP intake (ptrend > 0.10 
for each of 12 separate tests). 
 
Discussion 
 The interim data obtained from the ongoing study described are consistent with the hypothesis that a PSA- 
related, and a combined PSA- and DRE-related, screening indicator of highly elevated PC risk is significantly 
Rev. 1.1:  13 Jan 2006 
 
33 
 
positively associated with estimated dietary exposure to PhIP.  Although this conclusion remains tentative in view of 
the fairly small number of men involved in this prospective study so far, it is supported by the consistency of the 
pattern of results found, their level of statistical significance, and the significant positive association observed 
between highly elevated PSA and a positive father/brother history of PC consistent with previous studies that clearly 
have linked this factor to elevated PC risk (see Introduction).   
 The results obtained seem to contradict those of the study comparing HA intake (primarily from cooked lamb) 
and PC risk in New Zeeland men (including 317 PC cases and 480 age-matched controls) studied by Norrish et al. 
(1999), who found no significant PhIP-related associations involving PC.  However, the lower bound on individual-
average daily PhIP intake (224 ng/d) that study used in its top exposure quartile that was about 12-fold lower than 
the lower bound (of about 2680 ng/d) of the top 15% (the highest category) of PhIP exposures estimated for the East 
San Francisco Bay area African-American men in the present study.  If the dose-response for PhIP-induced 
elevation of PC risk were assumed to be linear no-threshold, linear extrapolation from significantly elevated OR 
estimates ≥ 2.2 or 3.2 obtained in the present study down to PhIP exposure levels used in the Norrish et al. (1999) 
study would require the latter study to be able to detect elevated OR values as low as about 1.2 or 1.3 in order to 
have detected a significant PhIP-related association with 95% confidence at 80% statistical power.  In contrast, exact 
evaluation of non-central hypergeometric distributions (Zelterman, 1999) corresponding to the Norrish et al. (1999) 
study design indicate it could only detect an OR as low as about 1.8 with 95% confidence at 80% power for 
comparisons involving its lowest vs. highest exposure quartiles.  Moreover, the empirical relation between 
mutagenic and carcinogenic potencies of genotoxic rodent-carcinogen chemicals, such as PhIP, suggests that the 
low-dose dose-response for cancer induction by such chemicals is likely to be sublinear in general (Bogen, 1993), 
which implies that the Norrish et al. (1999) design had even less power to detect elevated PC risk due to PhIP 
exposure levels studied. 
 Ideally, a prospective study accumulates definitive diagnostic data together with data on exposure- or 
treatment-related variables of interest.  A key limitation to interpretation of data obtained in this study so far is thus 
that, despite ongoing work to obtain corresponding follow-up diagnostic data, a PC diagnosis is not yet (and for 
some, may never be) available for all participants who received either positive or highly elevated PC screening 
results or who received a “suspicious” DRE leading to medical referral.  Compared to a case-control design, the 
prospective design used in this ongoing study has the advantage of being double blind, insofar as PC screening 
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results analyzed are in each case known neither by the participant nor by study investigators until after each 
participant provides dietary survey data.  This design eliminates potential bias (e.g., in participants’ self-reported 
cooking preferences) associated with knowledge of PC-screening results or PC status, which is important in view of 
evidence that prior knowledge of cancer-related status can affect dietary recall and so induce significant differential 
misclassification (Wilkens et al., 1992).   
 In conclusion, we applied methods for estimating HA concentrations in cooked meats based on individually 
expressed data on meat-specific intakes, cooking methods and doneness preferences to estimate daily PhIP intakes, 
and observed these intake estimates to be positively associated with screening indicators of highly elevated PC risk 
in a prospective clinic-based PC screening study involving nearly 400 African-American men in the San Francisco 
East Bay area.  The observed positive association, which was most significant among men 55 to 70 years of age 
(ptrend = 0.00020), remained statistically significant after adjustments for saturated fat intake, total energy intake and 
self-reported father/brother history of PC.  Future work will continue to accrue participants in this study, expand the 
screening indicators used to predict PC status, and assess whether the observed PhIP-related association pertains as 
well to incident PC disease. 
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Table 1.  Estimated mean HA intakes by all 21,858 CSFII participants who consumed HAs, by age group. 
Variablea Value(s) n Mean 
39 to 50 115 47.2 
51 to 60 216 54.6 
61 to 70 61 63.6 
Age (y) 
All 392 53.9 
Weight (kg) 54.4 to 163 392 85.7c 
<30 317 25.2 
≥30 75 33.9 BMI (kg cm-2) 
18.4 to 46.0 392 26.9 
< 2 328 0.79 
2 to <4 42 2.7 
4 to <10 10 5.5 
10 to <20 7 14 
PSA (ng/mL) 
≥20 5 47 
  PSA<4 PSA≥4a 
Normal 233 15 
BPH 108 4 DRE 
Suspiciousa 12 3 
No 333 15 
Family historyb 
Yes 37 7 
a BMI = body mass index; DRE = digital rectal exam; Suspicious = abnormal DRE result leading to medical 
referral; Normal = no urinary, BPH or other symptoms. Each abnormal PSA result (≥4.0 ng/mL) triggered referral 
for medical follow-up. 
b Family history = self reported brother(s) and/or father diagnosed with prostate cancer. Association of positive 
family history with PSA ≥ 4 ng/mL is significantly positive by 2-tail Fisher exact test (p = 0.013). 
c Weight median (interquartile range) = 83.9 (74.8 to 95.3) kg. 
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Table 2.  Summary of meat-specific PhIP intakes for 392 study subjects. 
Meat type 
 Chicken Burger Beef Pork Fish Bacon All 
Mean 10.3 2.54 2.39 0.34 0.36 0.02 16.7 
SD 12.7 3.73 4.32 0.58 1.02 0.13 16.9 
SDM 0.64 0.19 0.22 0.03 0.05 0.01 0.85 
CVM% 6.24 7.41 9.12 8.22 14.6 30.1 5.11 
%All 61.5 15.2 14.3 2.16 2.18 0.13 100. 
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Table 3.  Association of PhIP intake with elevated PSA. 
Adjustment or 
restrictiona      . 
PSA ≥ 20 
ng/mLb     
    Ave. PhIP intakea 
   PR      (ng kg-1 d-1) m n ORc 95%LCLc 95%UCLc ptrendc 
All data       
    0-50:              4.8 0 196 1    
    >50-70:       14.6 1 78 7.6 0.47 200  
    >70-85:       25.5 1 59 10. 0.62 260  
   >85-100:     49.7 3 59 24. 2.2 540 0.0024 
Adj. for FH   
    (same as above) (m, n, ORs, LCLs and UCLs unchanged) 0.0026 
FH –       
    0-50:              4.8 0 174 1    
    >50-70:       14.6 1 69 7.6 0.47 200  
    >70-85:       25.5 1 53 9.8 0.61 260  
   >85-100:     49.7 1 52 10. 0.63 260 0.14 
FH +       
    0-50:              4.8 0 22 1    
    >50-70:       14.6 0 9 – – –  
    >70-85:       25.5 0 6 – – –  
   >85-100:     49.7 2 7 18. 1.4 540 0.0024 
Adj. for SatFat       
    0-50:              4.8 0 196 1    
    >50-70:       14.6 1 78 3.4 0.21 89.  
    >70-85:       25.5 1 59 4.1 0.26 110  
   >85-100:     49.7 3 59 24. 2.2 540 0.014 
Adj. for KCAL       
    0-50:              4.8 0 196 1    
    >50-70:       14.6 1 78 14. 0.85 360  
    >70-85:       25.5 1 59 4.3 0.27 110  
   >85-100:     49.7 3 59 24. 2.2 540 0.0030 
       
a PR = percentile range; FH = family history (self reported brother/s and/or father diagnosed with prostate cancer; 
SatFat = daily saturated fat intake per kg body weight; KCAL = total energy intake per kg body weight.  Trend 
analyses adjusting for SatFat or KCAL were each done using the adjustment variable dichotomized at its median 
value. 
b m = number with PSA ≥ 20 ng/mL among n total participants included in the analysis. 
c OR = maximum likelihood odds ratio estimate; CL = confidence limit; LCL = lower CL; UCL = upper CL; ptrend = 
p-value for chi-square test of linear, or (as indicated) adjusted linear, trend. 
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Table 4.  Association of PhIP intake with elevated PSA in men ≥ 55 years old.  
Adjustment or 
restrictiona      . 
PSA ≥ 20 
ng/mLb     
    Ave. PhIP intakea 
   PRa     (ng kg-1 d-1) m n ORa 95%LCLa 95%UCLa ptrenda 
All data       
    0-50:              4.6 0 83 1    
    >50-70:       14.4 1 33 7.6 0.47 200  
    >70-85:       24.0 0 25 – – –  
   >85-100:     47.7 4 26 32. 3.2 720 0.00020 
Adj. for FH   
    (same as above) (m, n, ORs, LCLs and UCLs approx. unchangedc) 0.00039 
FH –       
    0-50:              4.6 0 76 1    
    >50-70:       14.4 1 27 8.5 0.52 220  
    >70-85:       24.0 0 22 – – –  
   >85-100:     47.7 2 22 18. 1.5 430 0.016 
FH +       
    0-50:              4.6 0 22 1    
    >50-70:       14.4 0 9 – – –  
    >70-85:       24.0 0 6 – – –  
   >85-100:     47.7 2 7 18. 1.4 540 0.0067 
Adj. for SatFat       
    0-50:              4.6 0 83 1    
    >50-70:       14.4 1 33 4.1 0.25 110  
    >70-85:       24.0 0 25 – – –  
   >85-100:     47.7 4 26 32. 3.2 720 0.0024 
Adj. for KCAL       
    0-50:              4.6 0 83 1    
    >50-70:       14.4 1 33 – – –  
    >70-85:       24.0 0 25 4.0 0.24 110  
   >85-100:     47.7 4 26 32. 3.2 720 0.0011 
       
a See Table 3 notes for column-header and acronym definitions.  
b m = number with PSA ≥ 20 ng/mL among n total participants included in the analysis. 
c At mean PhIP-intake level 14.4 ng kg-1 d-1, OR (95%CL) = 8.5 (0.52, 220). 
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Table 5.  Association of PhIP intake with elevated PSA or with suspiciousa DRE. 
Adjustment or 
restrictiona     . 
PSA ≥ 20 
ng/mL or 
suspicious DREb     
    Ave. PhIP intakea 
   PR      (ng kg-1 d-1) m n ORa 95%LCLa 95%UCLa ptrenda 
All data       
    0-50:              4.8 5 187 1    
    >50-70:       14.6 5 75 2.6 0.58 11.  
    >70-85:       25.5 3 58 2.0 0.30 11.  
   >85-100:     49.7 7 57 5.1. 1.3 21. 0.0063 
Adj. for SatFat   
   (same as above) (m, n, ORs, LCLs and UCLs unchanged) 0.036 
Adj. for KCAL   
   (same as above) (m, n, ORs, LCLs and UCLs unchanged) 0.0063 
Adj. for FH   
   (same as above) (m, n, ORs, LCLs and UCLs unchanged) 0.0077 
FH –       
    0-50:              4.8 3 168 1    
    >50-70:       14.6 5 67 4.4 0.82 29.  
    >70-85:       25.5 2 52 2.2 0.17 20.  
   >85-100:     49.7 4 50 4.7 0.77 34. 0.066 
FH +       
    0-50:              4.8 2 19 1    
    >50-70:       14.6 0 8 0.42 0.02 5.5  
    >70-85:       25.5 1 6 1.7 0.02 39.  
   >85-100:     49.7 3 7 5.8 0.50 93. 0.036 
       
a See Table 3 notes for column-header and acronym definitions. DRE = digital rectal exam; “suspicious” = abnormal 
DRE result leading to medical referral. 
b m = number with PSA ≥ 20 ng/mL among n total participants included in the analysis. 
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Figure Legends 
Figure 1.  Cumulative distributions of estimated PhIP intake by meat type for the study population of 392 Oakland, 
CA-area African-American men.  Curves with increasing boldness denote the following meat types (and 
corresponding % of total estimated intake): burger (15%), other beef (14%), chicken (61%), and total (100%). 
 
Figure 2.   Ratio of total to basal energy intake (in kcal per kg body weight per day) estimated for the study 
population of 392 Oakland, CA-area African-American men.  The arithmetic mean value (solid line and points) is 
compared to the expected reference value of 1.6 (dashed lines. 
 
Figure 3.   PhIP intakes estimated using all meat- and cooking-method-specific doneness information (PhIPin), are 
compared to corresponding intake estimates (PhIPinc) each conditioned on meat- and cooking-method-specific PhIP 
concentrations that were averaged over all participants (i.e., over concentration differences associated with 
differences in their individually reported doneness preferences).  Fitted linear regression (dashed line), with intercept 
and slope (and corresponding 95%CL) estimates of -0.58 (-1.4, 0.23) and 1.01 (0.974, 1.045), respectively, is not 
significantly different from an identity relation (solid line). 
 
Figure 4.   Saturated fat (g/kg-d) intake estimated by FFQ vs. PhIP intake estimated by the LLNL Meat 
questionnaire for 392 Oakland, CA-area African-American men (open points).  Linear regression shown (solid line) 
indicates a significantly positive association. A single point (closed circle) determined to be an outlier (p < 10-5 by F 
test) was excluded from the regression analysis. 
 
Figure 5.  Cumulative distributions of PSA measured in 392 Oakland, CA-area African-American men who did (FH 
+), vs. who who did not (FH –), report a father and/or brothers diagnosed with prostate cancer. 
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